Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Earnings Data
Report Date
Nov 10, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
1.63Last Year’s EPS
1.27Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant revenue and royalty growth, successful share repurchase initiatives, and promising developments in key products and the pipeline. However, challenges remain with ongoing IP litigation with Merck and potential regulatory impacts from CMS guidance. Despite these challenges, the overall sentiment remains positive due to the outweighing positive financial and operational achievements.Company Guidance
Record-Breaking Revenue and Growth
Total revenue for the quarter was $326 million, representing a 41% increase over the second quarter of the prior year. Royalty revenue grew by 65% year-over-year to $206 million. Adjusted EBITDA increased by 65% over the prior year second quarter to $226 million.
Increased Financial Guidance
Halozyme raised its 2025 financial guidance for the second time this year, projecting total revenue of $1.275 billion to $1.355 billion, representing 26% to 33% growth over 2024. Full year royalty revenue guidance increased to $825 million to $860 million, representing growth of 44% to 51%.
Successful Share Repurchase Program
Completed the second $250 million share repurchase tranche of the authorized $750 million share repurchase plan and initiated the third $250 million share repurchase program under the approved $750 million plan.
Strong Performance in Key Products
DARZALEX revenue increased almost 22% to $3.5 billion in the quarter. Phesgo revenue grew by 55% year-over-year. VYVGART Hytrulo sales increased by 97% year-over-year.
Pipeline and New Growth Catalysts
14 catalysts have occurred or are expected throughout the year, with 11 already realized. New product approvals and indication expansions are driving significant revenue growth potential.
HALO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HALO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 05, 2025 | $60.81 | $62.32 | +2.48% |
May 06, 2025 | $59.38 | $70.14 | +18.12% |
Feb 18, 2025 | $57.90 | $57.77 | -0.22% |
Oct 31, 2024 | $50.57 | $57.15 | +13.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Halozyme Therapeutics (HALO) report earnings?
Halozyme Therapeutics (HALO) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).
What is Halozyme Therapeutics (HALO) earnings time?
Halozyme Therapeutics (HALO) earnings time is at Nov 10, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HALO EPS forecast?
HALO EPS forecast for the fiscal quarter 2025 (Q3) is 1.63.